- RecruitingTherapeutic exploratory (Phase II)
Isatuximab in type I cryoglobulinemia: A prospective pilot study / ICE STUDY
This study is looking at a new medicine called Isatuximab for people with a rare condition called type I cryoglobulinemia. It aims to see how well the medicine can reduce symptoms of blood vessel inflammation (vasculitis) and if it is safe to use. This is an early-stage study.
For: Isatuximab in type I cryoglobulinaemia: A prospective pilot studyFrance - RecruitingPHASE2
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
This study looks at a new drug combination (Isatuximab, Iberdomide, and Dexamethasone) for people with early-stage, "smouldering" myeloma that has a higher chance of turning into active myeloma. It aims to see if these drugs can stop or slow down the disease's progression.
For: Smouldering MyelomaUnited Kingdom - Active not recruitingPHASE2
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
This study is looking at a new combination of four medicines (Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone) for people with newly diagnosed, high-risk multiple myeloma. It aims to see how safe and effective this treatment is.
For: Multiple MyelomaGermany - RecruitingPHASE2
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
This study is testing a new drug, Isatuximab, for adults with a type of blood cancer called T-cell Acute Lymphoblastic Leukemia (T-ALL) that has come back or isn't responding to treatment. It looks at two groups of patients to see if the drug can help.
For: T-ALLGermany - RecruitingPHASE3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This study is for people recently diagnosed with a type of blood cancer called multiple myeloma who can't have a stem cell transplant. It compares a new medicine called AZD0120 with current standard treatments to see if it works better at controlling the cancer and keeping people well for longer.
For: Newly Diagnosed Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
This study compares two treatments for multiple myeloma: iberdomide alone versus iberdomide plus isatuximab. It looks at how well these treatments reduce leftover cancer cells after a stem cell transplant, aiming to find the best long-term care.
For: Multiple MyelomaAustria · Germany - Active not recruitingPHASE3
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
This study looks at adding a new drug, Isatuximab, to standard treatment for newly diagnosed multiple myeloma. It aims to see if Isatuximab improves outcomes both during initial treatment and during ongoing maintenance therapy.
For: Multiple MyelomaGermany - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
This study is looking at a new combination of two drugs, belantamab mafodotin and isatuximab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to find the safest and most effective dose.
For: Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
This study looks at new drug combinations with isatuximab and other treatments for a type of blood cancer called multiple myeloma. It aims to find better ways to treat patients whose cancer has come back or hasn't responded to previous treatments.
For: Plasma Cell Myeloma RefractoryUnited States · Australia · France